Valuation: Bicycle Therapeutics plc

Market Cap 260M 229M 217M 197M 369M 24.92B 372M 2.6B 1B 12.72B 975M 954M 40.95B P/E 2026 *
-1.43x
P/E 2027 * -1.58x
Enterprise Value -253M -223M -211M -192M -359M -24.29B -363M -2.54B -977M -12.4B -951M -930M -39.91B EV / Sales 2026 *
-14.4x
EV / Sales 2027 * -21.5x
Free-Float
71.25%
Yield 2026 *
-
Yield 2027 * -
1 day-1.62%
1 week-2.14%
Current month-11.62%
1 month-11.62%
3 months-12.05%
6 months-15.90%
Current year-48.45%
1 week 3.57
Extreme 3.57
3.95
1 month 3.57
Extreme 3.57
4.39
Current year 3.57
Extreme 3.57
7.34
1 year 3.57
Extreme 3.57
9.16
3 years 3.57
Extreme 3.57
28.67
5 years 3.57
Extreme 3.57
62.08
10 years 3.57
Extreme 3.57
62.08
Manager TitleAgeSince
Chief Executive Officer 57 01/09/2015
Director of Finance/CFO 46 29/01/2026
Chief Tech/Sci/R&D Officer - 01/06/2025
Director TitleAgeSince
Director/Board Member 57 01/09/2015
Director/Board Member 63 17/03/2021
Director/Board Member 69 20/02/2024
Date Insider Type Main position Quantity % Market Cap. Importance
15/7/26 Free

CHIEF PROD & SUPPLY CHAIN OFF

60,000 0.1580%
15/7/26 Free

Chief Technology Officer

60,000 0.1580%
15/7/26 Free

Chief Operating Officer

60,000 0.1580%
Change 5-day change 1-year change 3-year change Capi.($)
-1.62%-2.14%-52.04%-81.83% 260M
-0.70%-4.35%+56.10%+86.42% 71.81B
+0.45%-2.26%+38.36%+87.74% 60.06B
+0.19%+0.94%+36.97%+21.32% 27.93B
-1.73%-4.30%-18.37%+357.94% 25.7B
-0.51%-2.28%+0.48%-9.27% 24.89B
+0.65%+2.52%+25.89%-6.99% 20.92B
+3.46%+3.91%+158.90%+337.81% 15.04B
+0.48%+0.86%+44.56%+168.42% 14.46B
+3.91%-4.56%-2.71%+506.41% 13.87B
Average +0.46%-0.60%+28.81%+146.80% 27.49B
Weighted average by Cap. +0.19%-1.74%+37.94%+128.80%

Financials

2026 *2027 *
Net sales 17.53M 15.47M 14.64M 13.28M 24.89M 1.68B 25.14M 176M 67.69M 859M 65.84M 64.4M 2.76B 6.69M 5.9M 5.58M 5.06M 9.5M 642M 9.59M 67M 25.82M 328M 25.12M 24.57M 1.05B
Net income -172M -152M -144M -130M -244M -16.51B -247M -1.72B -664M -8.43B -646M -632M -27.13B -175M -155M -146M -133M -249M -16.8B -251M -1.75B -676M -8.58B -657M -643M -27.61B
Net Debt -513M -453M -428M -388M -728M -49.21B -735M -5.14B -1.98B -25.13B -1.93B -1.88B -80.86B -403M -356M -337M -305M -573M -38.7B -578M -4.04B -1.56B -19.76B -1.51B -1.48B -63.6B
Logo Bicycle Therapeutics plc
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating zelenectide pevedotin, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology.
Employees
288
Date Price Change Volume
30/09/26 USD 3.650 -1.62% 206,180
28/09/26 USD 3.710 +0.68% 442,525
25/09/26 USD 3.685 -1.21% 238,876
24/09/26 USD 3.730 +3.61% 820,636
23/09/26 USD 3.600 -3.49% 374,248
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
3.710USD
Average target price
9.500USD
Spread / Average Target
+156.06%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BCYC Stock